- Home
- IMRN vs SRFM Comparison
IMRN vs SRFM Comparison
Compare IMRN & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- SRFM
- Stock Information
- Founded
- IMRN 1994
- SRFM 2011
- Country
- IMRN Australia
- SRFM United States
- Employees
- IMRN N/A
- SRFM N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- SRFM Transportation Services
- Sector
- IMRN Health Care
- SRFM Consumer Discretionary
- Exchange
- IMRN Nasdaq
- SRFM Nasdaq
- Market Cap
- IMRN 14.4M
- SRFM 191.9M
- IPO Year
- IMRN N/A
- SRFM 2023
- Fundamental
- Price
- IMRN $2.10
- SRFM $3.96
- Analyst Decision
- IMRN
- SRFM Buy
- Analyst Count
- IMRN 0
- SRFM 4
- Target Price
- IMRN N/A
- SRFM $5.75
- AVG Volume (30 Days)
- IMRN 96.3K
- SRFM 3.5M
- Earning Date
- IMRN 08-29-2025
- SRFM 11-13-2025
- Dividend Yield
- IMRN N/A
- SRFM N/A
- EPS Growth
- IMRN N/A
- SRFM N/A
- EPS
- IMRN N/A
- SRFM N/A
- Revenue
- IMRN $4,777,422.00
- SRFM $107,372,000.00
- Revenue This Year
- IMRN N/A
- SRFM N/A
- Revenue Next Year
- IMRN N/A
- SRFM $18.06
- P/E Ratio
- IMRN N/A
- SRFM N/A
- Revenue Growth
- IMRN 48.63
- SRFM N/A
- 52 Week Low
- IMRN $1.50
- SRFM $1.50
- 52 Week High
- IMRN $2.48
- SRFM $9.91
- Technical
- Relative Strength Index (RSI)
- IMRN 49.77
- SRFM 38.83
- Support Level
- IMRN $2.09
- SRFM $4.07
- Resistance Level
- IMRN $2.24
- SRFM $4.50
- Average True Range (ATR)
- IMRN 0.13
- SRFM 0.45
- MACD
- IMRN -0.02
- SRFM -0.13
- Stochastic Oscillator
- IMRN 30.00
- SRFM 0.45
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.